Does Humana Cover Trulicity? Formulary Tier, Prior Auth, and Appeal Steps

How Humana Classifies Trulicity on Its Formulary

Humana places Trulicity on either Tier 3 (preferred brand) or Tier 4 (non-preferred brand), depending on the specific plan document. Tier 3 copays on a typical Humana Choice PPO run between $40 and $75 per fill, while Tier 4 copays can reach $100 to $150. The exact tier appears in the Summary of Benefits your plan mailed at enrollment or in the online drug-cost estimator on Humana's member portal.

Humana updates its formulary at least once per calendar year, and mid-year changes can shift a drug's tier or add new prior-authorization requirements. The 2025 Humana National Formulary lists dulaglutide under "GLP-1 receptor agonists, non-insulin antidiabetic agents" with quantity limits of four pens per 28 days [1]. For Medicare Advantage enrollees, the Part D formulary is the controlling document, and CMS requires that at least one GLP-1 agonist remain available in each formulary class [2].

Because formulary placement varies by state and by whether you hold a commercial HMO, PPO, or Medicare Advantage plan, the single most reliable step is to log into MyHumana and search for "dulaglutide" in the formulary lookup tool. If Trulicity appears with a "PA" flag, your prescriber will need to submit clinical documentation before the pharmacy can dispense it. A "ST" flag means step therapy applies.

Prior-Authorization Criteria for Trulicity on Humana

Humana requires prior authorization for Trulicity on most plan types. The approval criteria center on a confirmed diagnosis of type 2 diabetes mellitus, an HbA1c at or above 7.0%, and documented intolerance or inadequate response to metformin at maximally tolerated doses [3]. The prescriber submits a PA request either by fax or through Humana's electronic PA portal (CoverMyMeds integration).

Typical turnaround is 48 to 72 hours for standard requests. Urgent requests tied to inpatient discharge or acute glycemic instability can receive a decision within 24 hours. The PA is usually valid for 12 months, after which a renewal requires updated lab work showing continued medical necessity.

Humana's clinical review team evaluates PA requests against criteria adapted from the American Diabetes Association's Standards of Care, which recommend GLP-1 receptor agonists as second-line therapy for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk [4]. The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 12% versus placebo over a median 5.4-year follow-up (HR 0.88 to 95% CI 0.79 to 0.99) [5]. Including this trial data in the PA letter can strengthen an approval, particularly for patients with existing cardiovascular disease.

"For patients with type 2 diabetes and established cardiovascular disease, GLP-1 receptor agonists with proven cardiovascular benefit are recommended independent of HbA1c," states the ADA's 2024 Standards of Care, Section 9 [4].

Step-Therapy Requirements: What Humana Expects You to Try First

Humana's step-therapy protocol for GLP-1 receptor agonists typically requires a trial of metformin (or documented contraindication) before approving Trulicity. Some plans add a second step requiring trial and failure of a sulfonylurea or an SGLT2 inhibitor. The rationale tracks with ADA guidelines positioning metformin as first-line pharmacotherapy for type 2 diabetes given its established efficacy, low cost, and decades of safety data [4].

A "trial and failure" means the patient used the step-therapy drug at adequate dose for at least 90 days without reaching the target HbA1c, or experienced a documented adverse effect that made continuation unsafe. Metformin-associated gastrointestinal intolerance (diarrhea, nausea, abdominal pain) at doses of 1 to 500 mg per day or higher satisfies this criterion if the prescriber documents it in the medical record.

Patients with an eGFR below 30 mL/min/1.73 m² have a labeled contraindication to metformin per the FDA prescribing information [6]. In these cases, Humana should waive the metformin step and move directly to PA review for Trulicity. If the plan denies this waiver, the prescriber can cite the FDA label and the ADA's recommendation to avoid metformin when eGFR falls below 30.

Step-therapy exceptions also apply when a patient transfers from another insurer where they were already stable on Trulicity. Humana's "continuity of care" provision allows a temporary 90-day supply while the new PA processes, though the prescriber must still submit the authorization request within the first 30 days.

Does Humana Cover Trulicity for Weight Loss?

No. Humana does not cover Trulicity for weight loss as an isolated indication. Dulaglutide is FDA-approved only for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes [7]. Unlike semaglutide 2.4 mg (Wegovy), dulaglutide does not carry an FDA-approved obesity indication.

For Humana Medicare Advantage enrollees, the restriction is even firmer. CMS prohibits Part D coverage of drugs used exclusively for weight loss under Section 1862(a)(1)(A) of the Social Security Act [2]. If the prescriber writes a diagnosis code for obesity (E66.01) without a co-listed type 2 diabetes code (E11.x), the claim will reject at the pharmacy level.

Humana commercial plans follow similar logic but with slightly more flexibility. If a patient has both type 2 diabetes and obesity, the prescriber can code the prescription under the diabetes indication, and the weight loss becomes a secondary clinical benefit rather than the stated reason for prescribing. The AWARD-11 trial showed that dulaglutide 4.5 mg (a higher dose not commercially available in the U.S.) produced 4.7 kg mean weight loss at 36 weeks in patients with type 2 diabetes [8]. At the approved 1.5 mg dose, mean weight reduction in REWIND was approximately 2.9 kg over the study period [5].

What Trulicity Costs on Humana Plans

The list price for Trulicity is approximately $931 per month for four single-dose pens [7]. What you actually pay depends on your plan's tier placement, deductible status, and whether you have reached the coverage gap (for Medicare Part D enrollees).

On a typical Humana commercial PPO with Tier 3 placement, expect a copay between $40 and $75 after meeting the annual deductible. Tier 4 placement raises that to $100 to $150. High-deductible plans may require you to pay the full negotiated rate (often $700 to $850) until you hit the deductible threshold.

For Medicare Advantage Part D enrollees, cost-sharing depends on the coverage phase. In the initial coverage phase, coinsurance for a Tier 4 drug runs approximately 25% to 40% of the plan's negotiated price. Once spending crosses the catastrophic threshold ($8 to 000 in true out-of-pocket costs for 2025), the enrollee pays 5% coinsurance or a small copay for the remainder of the year [2].

Eli Lilly offers a manufacturer savings card that can reduce commercial copays to as little as $25 per month for eligible patients [7]. This card cannot be used with Medicare, Medicaid, Tricare, or any other government-funded insurance. Humana commercial members who face high copays should ask their pharmacist to run the savings card as a secondary payer.

"Manufacturer copay cards can meaningfully reduce out-of-pocket burden for commercially insured patients on branded GLP-1 receptor agonists, but they do not reduce the total cost to the health system," notes a 2023 analysis published in JAMA Internal Medicine [9].

How to Appeal a Humana Denial of Trulicity

A denial is not the end. Humana's appeal process has two internal levels for commercial plans and a Medicare-specific external route for MA enrollees. Start with the denial letter itself. It contains the clinical rationale for the decision and a deadline (usually 180 days for commercial, 60 days for Medicare Part D).

Internal Appeal, Level 1. The prescriber submits a letter of medical necessity with supporting documentation: recent HbA1c values, medication history showing metformin failure or intolerance, cardiovascular risk factors, and relevant trial data. Citing REWIND outcomes (12% reduction in MACE, HR 0.88) strengthens the argument for cardiovascular benefit in at-risk patients [5]. Humana must respond within 30 calendar days for a standard appeal or 72 hours for an expedited appeal.

Internal Appeal, Level 2. If Level 1 is denied, the member can request a second review by a different clinical reviewer. The same 30-day (standard) or 72-hour (expedited) timeline applies.

External Review (Medicare). Medicare Advantage enrollees who exhaust internal appeals can escalate to an Independent Review Entity. For Part D disputes, the external review is handled by MAXIMUS, the CMS-contracted adjudicator. MAXIMUS reviews are de novo, meaning the reviewer considers all evidence without deference to Humana's prior decisions. Success rates at the MAXIMUS level for GLP-1 agonist denials have historically run between 40% and 60%, according to CMS data on Part D coverage determinations [10].

Throughout this process, the prescriber can request a temporary supply exception so the patient does not gap therapy while the appeal is pending. Abrupt discontinuation of GLP-1 agonists in patients with type 2 diabetes can cause glycemic rebound, and clinical guidelines recommend avoiding therapy interruptions whenever possible [4].

Alternatives if Humana Denies Trulicity

If appeals fail or the out-of-pocket cost remains too high, several alternatives exist within the GLP-1 receptor agonist class. Semaglutide (Ozempic) is another once-weekly injectable with cardiovascular benefit data from the SUSTAIN-6 trial (HR 0.74 for MACE, N=3,297) [11]. Humana formularies sometimes prefer Ozempic over Trulicity or vice versa, so a simple formulary swap may resolve the access issue.

Oral semaglutide (Rybelsus) offers a non-injectable option and may sit on a different formulary tier. Liraglutide (Victoza) is the once-daily GLP-1 agonist with LEADER trial data showing a 13% MACE reduction (HR 0.87, N=9,340) [12]. Exenatide extended-release (Bydureon BCise) is typically placed on a lower formulary tier but lacks dedicated cardiovascular outcome trial data showing superiority over placebo.

For patients with strong cardiovascular indications, the ADA recommends selecting a GLP-1 agonist with proven MACE benefit, which narrows the practical choices to dulaglutide, semaglutide, or liraglutide [4]. The prescriber should document why the specific agent matters when requesting PA for any of these alternatives.

If cost is the primary barrier and the patient is uninsured or underinsured, Eli Lilly's Lilly Cares Foundation offers a patient assistance program that provides Trulicity at no cost to qualifying individuals with household income at or below 400% of the federal poverty level [7].

Comparing Humana's Trulicity Policy to Other Major Insurers

Humana's approach to Trulicity coverage is broadly similar to UnitedHealthcare, Aetna, and Cigna in requiring PA and step therapy through metformin. Where Humana occasionally differs is in the number of step-therapy layers. Some Humana Medicare Advantage plans require documented failure of two oral agents (metformin plus a sulfonylurea or SGLT2 inhibitor) before approving any injectable GLP-1, while UnitedHealthcare's standard commercial policy requires only metformin failure.

Blue Cross Blue Shield plans vary by state but tend to place Trulicity on Tier 3 with a single-step metformin requirement. Aetna's 2025 commercial formulary lists Trulicity as non-preferred brand (Tier 4) with PA and step therapy, making Humana's Tier 3 placement on some plans comparatively favorable.

The key variable is always the specific plan document. Two Humana members in the same state can have different tier placements and PA criteria if they hold different plan products. Checking your plan's formulary before the prescriber writes the script prevents surprise costs at the pharmacy counter.

Across all major commercial insurers, the REWIND cardiovascular data remains the strongest clinical lever for PA approval. A 2022 retrospective analysis of PA outcomes across five large insurers found that including cardiovascular outcome trial data in the initial submission increased first-pass approval rates by 23 percentage points compared to submissions citing only glycemic control [13].